Ligand Pharmaceuticals Inc. Research Report
On December 5, 2013, Ligand Pharmaceuticals Inc.'s (Ligand Pharmaceuticals) stock increased 2.52%, closing the day's trading at $56.52. The Company's stock, however, declined 0.16% over the past three trading days, compared to the Nasdaq Composite Index which ended 0.30% lower during the same trading period. The Full Research Report on Ligand Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Masimo Corporation Research Report
On November 22, 2013, Masimo Corporation (Masimo) announced that ACUTRONIC Medical Systems AG has integrated Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry into ACUTRONIC's fabian HFO Neonatal Critical Care Ventilator for improved patient outcomes. According to the Company, the combined technology platform will optimize patient assessments and improve workflow, which allows clinicians to spend more time tending to patients. Masimo's President of Worldwide OEM Business & Corporate Development, Rick Fishel, stated, "The synergies realized between our companies and products support Masimo's mission to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. We are very pleased that Masimo's SET® Pulse Oximetry platform is a key component in ACUTRONIC's new neonatal ventilators." The Full Research Report on Masimo Corporation - includi
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved